Abstract
We explore a standard epidemiological model, known as the SIRD model, to study the COVID-19 infection in India, and a few other countries around the world. We use (a) the stable cumulative infection of various countries and (b) the number of infection versus the tests carried out to evaluate the model. The time-dependent infection rate is set in the model to obtain the best fit with the available data. The model is simulated aiming to project the probable features of the infection in India, various Indian states, and other countries. India imposed an early lockdown to contain the infection that can be treated by its healthcare system. We find that with the current infection rate and containment measures, the total active infection in India would be maximum at the end of June or beginning of July 2020. With proper containment measures in the infected zones and social distancing, the infection is expected to fall considerably from August. If the containment measures are relaxed before the arrival of the peak infection, more people from the susceptible population will fall sick as the infection is expected to see a three-fold rise at the peak. If the relaxation is given a month after the peak infection, a second peak with a moderate infection will follow. However, a gradual relaxation applied well ahead of peak infection, leads to a two-fold increase in the peak infection. The projection of the model is highly sensitive to the choice of the parameters and the available data. Our model provides a semi-quantitative overview of the progression of COVID-19 in India, with model projections reasonably replicating the current progress. However, since the pandemic is an ongoing dynamic phenomenon, the reported results are subjected to regular updates in consonance with the acquired real data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Saptarshi Chatterjee and Apurba Sarkar were supported by a fellowship from the University Grants Commission (UGC), India. Mintu Karmakar was supported by a fellowship from CSIR, India. Swarnajit Chatterjee thanks Indian Association for the Cultivation of Science, Kolkata for financial support. Raja Paul thanks IACS for support and Grant No. EMR/2017/001346 of SERB, DST, India for the computational facility.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The working institute Indian Association for the Cultivation of Science, Kolkata, India has approved the research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The real data for analysis in India's context is collected from the repository with an interactive interface hosted at https://www.covid19india.org. The data for other countries are taken from the repository with an interactive interface hosted at https://www.worldometers.info/coronavirus.
